Wall Street analyst estimates for Organon & Co. (OGN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio).
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $0.91 | ||
| 2026-07-31 | $0.85 | $0.85 | +0.0% |
| 2026-04-30 | $0.71 | $0.83 | -14.5% |
| 2026-02-12 | $0.63 | $0.73 | -13.7% |
| 2025-11-10 | $1.01 | $0.93 | +8.6% |
| 2025-08-05 | $1.00 | $0.94 | +6.4% |
| 2025-05-01 | $1.02 | $0.89 | +14.6% |
| 2025-02-13 | $0.90 | $0.92 | -2.2% |
Valuation Ratios
| P/E Ratio | 17.31 |
| Price / Book | 3.57 |
| EV / EBITDA | 7.87 |
| Dividend Yield | 0.59% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.50B | $9.78B | $7.78B | $6.53B | $6.30B | $6.17B | $6.26B | $6.40B | $6.22B |
| Cost of Revenue | $4.59B | $4.69B | $2.27B | $2.12B | $2.38B | $2.29B | $2.52B | $2.69B | $2.85B |
| Gross Profit | $5.91B | $5.08B | $5.50B | $4.41B | $3.92B | $3.88B | $3.75B | $3.71B | $3.36B |
| Research & Development | $355.0M | $365.0M | $220.0M | $210.0M | $443.0M | $471.0M | $528.0M | $469.0M | $366.0M |
| Selling, General & Admin | $2.29B | $2.01B | $1.44B | $1.36B | $1.67B | $1.70B | $1.89B | $1.76B | $1.71B |
| Operating Expenses | $2.64B | $2.38B | $1.66B | $1.57B | $2.01B | $2.17B | $2.42B | $2.23B | $2.09B |
| Operating Income | $3.27B | $2.71B | $3.85B | $2.85B | $1.92B | $1.71B | $1.33B | $1.49B | $1.28B |
| EBITDA | $5.08B | $4.38B | $3.92B | $2.99B | $1.98B | $1.76B | $1.44B | $1.60B | $1.28B |
| Interest Expense | 0 | 0 | $6.0M | $6.0M | $258.0M | $422.0M | $527.0M | $520.0M | $504.0M |
| Pre-tax Income | $3.10B | $2.73B | $3.70B | $2.75B | $1.53B | $1.12B | $673.0M | $807.0M | $425.0M |
| Income Tax | $1.30B | $576.0M | $390.0M | $496.0M | $178.0M | $205.0M | -$350.0M | -$57.0M | $238.0M |
| Net Income | $1.80B | $2.15B | $3.22B | $2.16B | $1.35B | $917.0M | $1.02B | $864.0M | $187.0M |
| EPS | $7.11 | $8.51 | $12.71 | $8.52 | $5.33 | $3.61 | $4.01 | $3.36 | $0.72 |
| EPS (Diluted) | $7.11 | $8.51 | $12.71 | $8.52 | $5.33 | $3.59 | $3.99 | $3.33 | $0.72 |
| Shares Outstanding (Diluted) | $253.1M | $253.1M | $253.1M | $253.5M | $253.6M | $255.2M | $256.3M | $259.2M | $260.8M |
Price
| Price | $13.67 |
| Market Cap | $3.6B |
| Exchange | NYSE |
| Country | US |
Related companies: ALVO · AUPH · AVDL · GRDN · HRMY · MD · NUVB
Explore sector: Healthcare · Drug Manufacturers - General
More sections of OGN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks